BioPartnering Europe 2006 Exhibitor Profiles.LONDON -- BioPartnering Europe 2006 takes place 8 - 10 October at the QEII Conference Centre in London. For in-depth information about the event, visit http://www.techvision.com/bpe/. Business Wire is the official news wire for BioPartnering Europe. Breaking news releases and photos are available at http://www.tradeshownews.com, Business Wire's trade show, conference, and event news resource. Below are profiles from BioPartnering Europe exhibitors. Company: Adnexus Therapeutics Media Contact: Katrine Bosley Phone: 781-891-3745 E-mail: pr@adnexustx.com Web: www.adnexustx.com Adnexus is focused on generating vital medicines through the commercialization of its new protein therapeutic class, Adnectins. Adnectins can address a broad range of diseases and surpass the limitations of other targeted therapeutics, such as antibodies. The intrinsic and predictable properties of the Adnectin product class align with the properties needed to make a successful drug, including high potency, specificity, stability, favorable half life, and high yield production. Adnexus has a pipeline of Adnectin products across several therapeutic areas. The portfolio is led by Angiocept (CT-322), which is in Phase 1 clinical development in oncology in the United States. Company: Ambit Biosciences Booth/Stand: Group 1, Booth 13 Media Contact: Rachel Lipsitz Phone: 619-849-5378 E-mail: rlipsitz@pnlifesciences.com Web: www.ambitbio.com With unprecedented speed and efficiency, Ambit's proprietary kinase platform, KinomeScan, identifies and quantifies binding interactions between small molecules and human proteins. KinomeScan has been validated through partnerships with Bristol-Myers Squibb Company, GlaxoSmithKline, Pfizer and Roche as well as articles in PNAS PNAS Proceedings of the National Academy of Sciences PNAS Phosphate:Na + Symporter PNAS Pensacola Naval Air Station PNAS Philippine National Airsoft Society and Nature Biotechnology. Ambit utilized KinomeScan to develop kinase inhibitors for the treatment of cancer and plans to initiate clinical trials in 2006. Ambit has raised a total of USD USD In currencies, this is the abbreviation for the U.S. Dollar. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 51 million from investors including Perseus-Soros Biopharmaceutical Fund, Forward Ventures, Roche, Avalon Ventures, MDS MDS, n See temporomandibular pain-dysfunction syndrome. MDS 1 Maternal deprivation syndrome, see there 2 Myelodysplastic syndrome, see there Capital, Genechem and GIMV NV. Company: Arrow Therapeutics Ltd Booth/Stand: OH Group 1, Booth 8 Media Contact: Annie Clayton Phone: +44 (0)20 7015 1000 E-mail: info@arrowt.co.uk Web: www.arrowt.co.uk Arrow Therapeutics is a London-based private discovery, research and development company focused on antiviral therapies in areas of significant unmet medical need. Arrow specializes in small molecule drugs with novel mechanisms of action and has a number of research and development programmes, the most advanced of which target Respiratory Syncytial Virus respiratory syncytial virus (sĭnsĭsh`əl): see cold, common. (RSV RSV respiratory syncytial virus; Rous sarcoma virus. RSV abbr. respiratory syncytial virus RSV 1 Respiratory syncytial virus, see there 2 Rous sarcoma virus, see there ) and Hepatitis C Virus
abbr. hepatitis C virus HCV 1 Hepatitis C virus, see there 2. Human coronavirus. See Coronavirus. ). Arrow's most advanced compound is RSV604, an RSV therapy currently undergoing Phase II clinical trials in partnership with Novartis. The Company's Hepatitis C Hepatitis C Definition Hepatitis C is a form of liver inflammation that causes primarily a long-lasting (chronic) disease. Acute (newly developed) hepatitis C is rarely observed as the early disease is generally quite mild. programme consists of multiple lead series from different chemical classes. The most advanced compounds inhibit NS5a, a novel viral target. The lead compound is now in the final stages of preclinical development and is planned to enter Phase I around October 2006. Arrow also has a Hepatitis C polymerase programme in lead optimization. Company: Avecia Booth/Stand: 12 Investor Relations Investor relations The process by which the corporation communicates with its investors. Contact: Duncan McLellan Phone: 01642 363511 E-mail: Biotech@avecia.com Web: www.avecia.com Avecia Biologics is a leader in contract process development and manufacturing services for microbially-derived and mammalian biologics at all stages of the product pipeline. With a substantial depth and breadth of expertise in developing innovative bioprocesses over 30 years, we work closely with our customers to achieve fast progress into and through the clinical development programme. We have particular strengths in E.coli and yeasts, with an outstanding capability in process and analytical science and technology. This is backed by cGMP manufacturing facilities at 100-1000 litre for Phase I/II materials and 300-5000 litres for Phase III and approved biologics, based in the North East of England The East of England is one of the nine official regions of England. It was created in 1994 and was adopted for statistics from 1999. It includes the ceremonial counties of Essex, Hertfordshire, Bedfordshire, Cambridgeshire, Norfolk and Suffolk. . Company: Favrille, Inc. Booth/Stand: Group 1, booth 21 Ticker Symbol Ticker Symbol An arrangement of characters (usually letters) representing a particular security listed on an exchange or otherwise traded publicly. When a company issues securities to the public marketplace, it selects an available ticker symbol for its securities which investors & Exchange: Nasdaq: FVRL FVRL Fort Vancouver Regional Library FVRL Fraser Valley Regional Library Media Contact: Pete De Spain Phone: (858) 526-2426 E-mail: pdespain@favrille.com Web: www.favrille.com Favrille is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial phase 3 clinical trial Phase 3 study. See Phase study. for patients with follicular fol·lic·u·lar adj. 1. Relating to, having, or resembling a follicle or follicles. 2. Affecting or growing out of a follicle or follicles. B-cell NHL NHL Non-Hodgkin's lymphoma, see there and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma Cutaneous T-Cell Lymphoma Definition Cutaneous T-cell lymphoma (CTCL) is a malignancy of the T-helper (CD4+) cells of the immune system. Description . Company: Haptogen Ltd Media Contact: Dr. Fiona Adair CBO CBO See: Collateralized Bond Obligation. Phone: +44 (0)1224 555 889 E-mail: fiona.adair@haptogen.com Web: www.haptogen.com Haptogen focuses on drug discovery and development of therapeutic antibodies that bind haptens and haptenic structures. This approach enables Haptogen to reach previously non-accessible targets. Haptogen focuses on infectious, renal and metabolic diseases. The company's technology, based on the propriety Haptomics platform, includes a unique phage display phage display n. A technique using recombinant DNA technology to create bacteriophages with a desired peptide embedded in the surface of their protein shells. technology - DBDx - to select antibodies against low-risk targets for its own product pipeline and partner targets. Haptogen is building value by advancing compounds for in-house development and partnering. Haptogen is led by highly experienced, commercially minded people with internationally recognized academic and scientific expertise. Company: hemoCORM Ltd Media Contact: Philip Ledger, PhD Phone: +44 1234 721 353E-mail: p.ledger@hemocorm.com Web: www.hemocorm.com hemoCORM Ltd is a London based company that has established a leading position in an exciting and emerging pharmacological field. The company is developing a novel class of therapeutic agents: compounds that release carbon monoxide (CO) under defined conditions. The compounds have been developed following the discovery that CO, like nitric oxide, is a naturally occurring chemical messenger that, in physiological doses, has anti-inflammatory, hypotensive hypotensive /hy·po·ten·sive/ (-ten´siv) marked by low blood pressure or serving to reduce blood pressure. hy·po·ten·sive adj. 1. Of or characterized by low blood pressure. 2. and anti-apoptotic properties and can suppress graft rejection and protect tissues from ischemic Ischemic An inadequate supply of blood to a part of the body, caused by partial or total blockage of an artery. Mentioned in: Antiangiogenic Therapy, Subarachnoid Hemorrhage, Ventricular Fibrillation ischemic damage. Company: Mimetogen Pharmacueticals Inc. Media Contact: Garth Cumberlidge Phone: +1 514 667 5869E-mail: ceo@mimetogen.com Web: www.mimetogen.com Privately held biotechnology drug development company with novel neuroprotectants entering clinical trials for primary open angle glaucoma. The company has developed a family of novel small molecule peptidomimetics that show strong efficacy in animal models of glaucoma and has discovered novel proteins that are responsible for the specific death of retinal ganglion cells, which cause the loss of vision associated with the disease. Currently raising Series B capital to fund phase I and II clinical trials for the first compound and to further develop the strong pipeline of novel compounds and molecular targets for the disease. Company: InterMune Ticker Symbol & Exchange: ITMN - NASDAQ Media Contact: Pam Lord of Porter Novelli Life Sciences Phone: +1-415-466-2242 E-mail: ir@intermune.com Web: www.intermune.com InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology pul·mo·nol·o·gy n. The branch of medicine that deals with diseases of the respiratory system. pulmonology The study of the lungs and respiratory function and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis idiopathic pulmonary fibrosis Idiopathic interstitial fibrosis of lung Pulmonology An idiopathic condition characterized by scarring and fibrosis of alveolar septae more common in middle-aged men, possibly related to collagen vascular disease, with positive (IPF (Itanium Processor Family) See Itanium. ) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes two Phase III programs evaluating possible therapeutic candidates for treatment of patients with IPF. The INSPIRE trial is evaluating Actimmune[R] (interferon gamma-1b) and the CAPACITY program is evaluating pirfenidone. The hepatology portfolio includes the lead HCV protease inhibitor compound ITMN-191, a second-generation HCV protease inhibitor program, and a research program evaluating a new target in hepatology. Company: Merrion Pharmaceuticals Limited Media Contact: John Lynch Phone: +353 1 672 9272 E-mail: info@merrionpharma.com Web: www.merrionpharma.com Merrion is an international specialty pharmaceutical company focused on developing oral drug products, because of the clear advantage to patients and healthcare professionals of oral delivery. We use advanced technologies to provide oral dosage forms of currently injectable drugs, and improved oral forms, where there is a clear unmet medical need. Merrion's technology and expertise also allow the oral delivery of a wide variety of biopharmaceuticals, and provide extended retention and release of drug in the stomach (>16 hours). Merrion's US headquarters are in Wilmington, NC, USA. The company's European headquarters, R&D and manufacturing operations are located in Dublin, Ireland. Company: NeoMPS SA Booth/Stand: No. 16, 10th Oct. 9:45 Media Contact: Serge Plaue Phone: +33 3 88 79 08 79 E-mail: neo@neomps.com Web: www.neomps.com NeoMPS: 20 years experience in peptide manufacturing and organic chemistry. Two GMP GMP (guanosine monophosphate): see guanine. plants: Strasbourg, France (inspected by the French Health Products Safety Agency) and San Diego, USA (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. inspected), assist customers with projects requiring peptides or small molecules for pre-clinical, clinical, or commercial applications. NeoMPS offers: - Research grade products - Lead optimization and innovative solutions for peptide development - GMP peptide manufacturing up to tens of kilograms (nearly 400 peptides manufactured for clinical trials) - Process R&D - Flexibility of solid and liquid phase chemistry - Full regulatory support (several filed DMFs) - Partnership approach focused on customer satisfaction. Company: Perceptronix Medical Inc Booth/Stand: 16 / Group 2 Media Contact: Ms. Rachel Mussard Investor Relations Contact: Ms. Larissa Thomas Phone: 604-707-9037 E-mail: info@perceptronix.com Web: www.perceptronix.com Perceptronix Medical Inc. is a Vancouver-based, privately-owned cancer diagnostic company founded in June 1999 as a spin off of the BC Cancer Agency. The Company's mission is to commercialize effective technologies to improve the early detection, localization Customizing software and documentation for a particular country. It includes the translation of menus and messages into the native spoken language as well as changes in the user interface to accommodate different alphabets and culture. See internationalization and l10n. , diagnosis and follow-up of cancer, with an initial focus on lung cancer. This disease has reached epidemic proportions and typically has a poor outcome (five year survival rate is less than 15%) because symptoms are not usually present until the disease is in an advanced stage. Company: PLx Pharma Media Contact: Ron Zimmerman Phone: 1-713-842-1249 E-mail: ron.zimmerman@plxpharma.com Web: www.plxpharma.com PLx Pharma is developing GI safer NSAIDs, drugs like ibuprofen ibuprofen (ī`by  prō'fən), nonsteroidal anti-inflammatory drug (NSAID) that reduces pain, fever, and inflammation. , aspirin and naproxen naproxen and naproxen sodium, potent nonsteroidal anti-inflammatory drugs (NSAID) used to alleviate the minor pain of arthritis, menstruation, headaches, and the like, and to reduce fever. . The firm's proprietary phospholipid phospholipid (fŏs'fōlĭp`ĭd), lipid that in its simplest form is composed of glycerol bonded to two fatty acids and a phosphate group. technology when complexed with traditional NSAIDs has clinically proven with the lead product, a GI safer novel ibuprofen formulation, to dramatically reduce GI toxicity in chronic use by arthritis patients over 55 years old. PLx is seeking a larger Pharmaceutical partner to continue commercialization of the lead product and broader pain & inflammation platform. Company: Psynova Media Contact: Paul Rodgers Phone: +44 1223 703146 E-mail: paul.rodgers@psynova.com Web: www.psynova.com Psynova is focused on the development and exploitation of biomarkers for neuropsychiatric neu·ro·psy·chi·a·try n. The medical study of disorders with both neurological and psychiatric features. neu conditions such as schizophrenia and bipolar disorder. These conditions are major disabilities, affecting at least 5-10% of the population worldwide and costing society hundreds of billions of pounds. Diagnosis and prognosis are complex and subjective, and diagnostic tests or medical interventions are non-existent or limited. Psynova intends to address this gap in our knowledge by identifying biomarkers that can be used in diagnosis, monitoring and the discovery and development of more effective drugs and to identify patient sub-groups that are responsive to particular drugs (i.e. personalized medicines). Company: Stem Cell Therapeutics Corp. Booth/Stand: Group 4, Booth 6 Ticker Symbol & Exchange: TSX-Venture: 'SSS' Media Contact: Chloe Douglas-Crampton Phone: 403-245-5495 E-mail: ir@stemcellthera.com Web: www.stemcellthera.com Stem Cell Therapeutics Corp. (SCT Sacrococcygeal teratoma (SCT) A tumor occurring at the base of the fetus's tailbone. Mentioned in: Prenatal Surgery ) is a clinical stage biotechnology company focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patients own resident stem cells. The company's programs aim to repair neurological function lost due to disease or injury. Our currently enrolling phase IIa clinical program for NTx[TM]-265 targets the treatment of stroke by repurposing approved and clinically well defined drugs. The company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases. Company: Tranzyme Pharma Booth/Stand: Group 1 Media Contact: Eric Nelson Investor Relations Contact: Richard Eisenstadt Phone: 919-313-4760 E-mail: enelson@tranzyme.com Web: www.tranzyme.com Tranzyme Pharma is focused on developing and commercializing novel small molecule therapeutics for the treatment of GI and metabolic diseases. The Company has built a pipeline of internally-discovered, first-in-class small molecule therapeutics targeting two validated and druggable GPCRs found within the GI tract: ghrelin and motilin. Tranzyme Pharma's most advanced product, TZP-101, is a potent prokinetic agent entering Phase II development for the treatment of acute GI motility motility /mo·til·i·ty/ (mo-til´ite) the ability to move spontaneously.mo´tile Motility Motility is spontaneous movement. disorders such as post-operative ileus Ileus Definition Ileus is a partial or complete non-mechanical blockage of the small and/or large intestine. The term "ileus" comes from the Latin word for colic. and acute gastroparesis. In addition, the Company's pipeline includes TZP-102 for chronic gastroparesis, TZP-201 for intestinal hypermotility, and TZP-301 for obesity. By targeting ghrelin and motilin receptors, Tranzyme's mechanism-based therapeutics directly act on the site of pathophysiological disturbance to treat the underlying condition and improve clinical outcome. Company: Trigen Booth/Stand: 10 Media Contact: Ashley Tapp, Head of Corporate Comms. Phone: +44 (0) 20 7004 2630 E-mail: atapp@trigen.co.uk Web: http://www.trigen.co.uk Trigen is a biopharmaceutical company, with operations in London and Munich, and a leader in cardiovascular drug discovery and development, focusing on thrombosis and vascular dysfunction. The company's product pipeline includes clinical stage candidates, TGN TGN Trans-Golgi Network TGN Tarragona (Catalonia, Spain) TGN Thesaurus of Geographic Names TGN The Good News (Catholic Diocese of Kalamazoo newspaper) TGn Task Group N (IEEE) 255, TGN 167 and PR-15 and also an extensive portfolio of exciting preclinical and discovery stage programmes targeting thrombosis, atherosclerosis and other cardiovascular pathologies. In addition, Trigen benefits from two established discovery platforms, SIGSCREEN[R] and THROMSCAN[R] which have been applied in collaborations with a number of multinational pharmaceutical companies. Company: Warwick Effect Polymers Ltd Booth/Stand: Open House 14, 10/10 Media Contact: Noru Tsalic Phone: +44 (0)24 7669 2476E-mail: n.tsalic@wep-ltd.co.uk Web: www.wep-ltd.co.uk Warwick Effect Polymers Ltd. (WEP (Wired Equivalent Privacy) An IEEE standard security protocol for wireless 802.11 networks. Introduced in 1997, WEP was found to be very inadequate and was superseded by WPA, WPA2 and 802.11i. ) is positioned at the interface between polymer technology and life sciences. Based on the pioneering work of Prof. Haddleton and his Polymer Group at the University of Warwick In the 1960s and 1970s, Warwick had a reputation as a politically radical institution.[3] More recently, the University has been seen as a favoured institution of the British New Labour government. , WEP's technology is able to generate tightly controlled polymer architectures. It also provides an elegant route to obtaining end-functional polymers, well suited for further, post-polymerization chemistry. This core capability has resulted in two major drug delivery applications. Our POLY PEG[R] family of novel PEGylation agents and technologies contributes to the development of safer and more efficacious protein- and peptide-based therapeutics. Our latest pipeline development is GLYCOPOL[TM], a family of novel glyco-polymers, with tremendous potential as targeted drug carriers. Company: XOMA Ltd. Booth/Stand: 10/9 10:00 AM, #17 Ticker Symbol & Exchange: XOMA Media Contact: PAUL GOODSON Phone: 1-510-204-7270 E-mail: GOODSON@XOMA.COM Web: WWW.XOMA.COM XOMA is a leader in the discovery, development and manufacturing of therapeutic monoclonal antibodies (mAbs). XOMA's mAb platform includes leading commercial antibody display phage phage: see bacteriophage. phage - A program that modifies other programs or databases in unauthorised ways; especially one that propagates a virus or Trojan horse. See also worm, mockingbird. The analogy, of course, is with phage viruses in biology. libraries, hybridoma hybridoma /hy·brid·o·ma/ (hi?brid-o´mah) a somatic cell hybrid formed by fusion of normal lymphocytes and tumor cells. hy·brid·o·ma n. , Human Engineering[TM], affinity maturation technologies, and a fully integrated product development infrastructure, including cell line and process development, preclinical and clinical functions, and manufacturing. XOMA's pipeline includes both proprietary products and collaborative programs. XOMA receives royalties for RAPTIVA[R] and LUCENTIS[TM]. Other strategic collaborations include Novartis (formerly Chiron Corp), Schering Plough and Lexicon Genetics. Company: Zyentia Limited Media Contact: Helen Kent (helen.kent@zyentia.com) Investor Relations Contact: JesE[bar]s Zurdo Phone: +44 (0) 1223 496787 E-mail: jesus.zurdo@zyentia.com Web: www.zyentia.com Zyentia is actively engaged in the development of solutions to protein misfolding and aggregation in human degenerative diseases and the improvement of biopharmaceuticals. Protein misfolding is of aetiological AE`ti`o`log´ic`al a. 1. Pertaining to ætiology; assigning a cause. Adj. 1. aetiological - of or relating to the philosophical study of causation aetiologic, etiologic, etiological 2. importance to a number of pathologies characteristic of aging and may be of central importance to the aging process itself. Zyentia has three active drug discovery programmes in Type 2 diabetes type 2 diabetes n. See diabetes mellitus. , Alzheimer's and Parkinson's diseases, which have completed early in vivo proof of concept. Zyentia also applies its proprietary AggreSolve[TM] platform to develop improved biologics, offering a variety of solutions to Pharmaceutical and Biotechnology companies developing biotherapeutics. Note to Editors: Business Wire's PressPass allows you to create free, custom Web, RSS (Really Simple Syndication) A syndication format that was developed by Netscape in 1999 and became very popular for aggregating updates to blogs and the news sites. RSS has also stood for "Rich Site Summary" and "RDF Site Summary. , and email-based news feeds from more than 160 industry options, dozens of subject categories and thousands of geographic preferences as well as by specific company filters. In addition, PressPass subscribers have access to exclusive content, experts, company profiles, email alerts, survey services and other media services. Note to Event Organizers: Add your trade show, conference, or event to www.tradeshownews.com, Business Wire's online event calendar. For information, email tradeshow@businesswire.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion